Literature DB >> 18722921

Pelvic perfusion for advanced colorectal cancers.

Giovanni Begossi1, James F Belliveau, Harold J Wanebo.   

Abstract

Isolated pelvic perfusion (IPP) is a form of intra-arterial local-regional treatment of tumor-bearing organs. IPP using a simplified balloon occlusion technique has shown promise in palliation of resectability of advanced rectal cancer in patients not amenable to treatment with conventional chemoradiation. This article reviews technique criteria and the response to IPP from seven literature studies of isolated pelvic perfusion with colorectal cancer. Current efforts should be directed to improving anti-tumor responses by optimizing chemotherapeutic protocols and modifying perfusion parameters, so that hopefully, this will lead to a more standardized and improved procedure for the isolated pelvic perfusion technique.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722921     DOI: 10.1016/j.soc.2008.04.014

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  6 in total

1.  Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study.

Authors:  Stefano Guadagni; Marco Clementi; Maria Bencivenga; Shigeki Kusamura; Caterina Fiorentini; Francesco Masedu
Journal:  Updates Surg       Date:  2018-09-06

Review 2.  Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.

Authors:  Shuang Cai; Taryn R Bagby; M Laird Forrest
Journal:  Ther Deliv       Date:  2011-11

3.  Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques.

Authors:  Stefano Guadagni; Giammaria Fiorentini; Marco Clementi; Paola Palumbo; Andrea Mambrini; Francesco Masedu
Journal:  Updates Surg       Date:  2017-08-08

4.  Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability.

Authors:  Stefano Guadagni; Giancarlo Palumbo; Giammaria Fiorentini; Marco Clementi; Luca Marsili; Aldo Victor Giordano; Francesco Masedu; Marco Valenti
Journal:  BMC Res Notes       Date:  2017-08-15

5.  Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study.

Authors:  Stefano Guadagni; Giammaria Fiorentini; Andrea Mambrini; Francesco Masedu; Marco Valenti; Andrew Reay Mackay; Donatella Sarti; Enrico Ricevuto; Marco Clementi; Marco Catarci; Gianni Lazzarin; Gemma Bruera
Journal:  Oncotarget       Date:  2019-06-11

6.  Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.

Authors:  Stefano Guadagni; Giammaria Fiorentini; Michele De Simone; Francesco Masedu; Odisseas Zoras; Andrew Reay Mackay; Donatella Sarti; Ioannis Papasotiriou; Panagiotis Apostolou; Marco Catarci; Marco Clementi; Enrico Ricevuto; Gemma Bruera
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-16       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.